在人类皮肤莱什曼病中治疗失败的先天生物标志
María Adelaida Gómez1,2, Ashton Trey Belew3,4, Deninson Alejandro Vargas5,6
1Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Cali, Colombia. mgomez@cideim.org.co.
Nature communications
|April 4, 2025
概括
一种增强的I型干扰素反应预测皮肤莱什曼病 (CL) 的治疗失败. 转录签名可以识别可能失败治疗的患者,指导未来的CL宿主导治疗.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 免疫反应决定了Leishmania感染的结果和治疗的有效性.
- 人类皮肤雷什曼病 (CL) 治愈和慢性免疫病理的基础机制尚不清楚.
研究的目的:
- 确定在CL中预测治疗失败 (TF) 的免疫机制和生物标志物.
- 探索I型干扰素反应在CL治疗结果中的作用.
主要方法:
- 在氨酸抗酸治疗期间对单细胞,中性粒细胞和氨基粒细胞进行序列转录基因分析.
- 在治疗前,治疗中和治疗结束样本中分析基因表达.
- 使用基因表达特征和机器学习模型开发预测生物标志物.
主要成果:
- 一种持续的I型干扰素反应特征是LC患者感染莱什马尼亚 (Viannia) 种的TF的标志.
- 11个差异表达基因的复合基因表达分数预测了TF.
- 机器学习模型使用转录数据准确地分类治疗结果 (治疗与TF).
结论:
- I型干扰素反应是宿主导的CL疗法的潜在免疫标.
- 转录签名提供了一个可行的方法来预测CL治疗结果,并为治疗决策提供信息.
相关概念视频
Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


